Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1204320080240010067
Laboratory Animal Research
2008 Volume.24 No. 1 p.67 ~ p.75
Effects of Red Ginseng Powder and Silk Peptide on Hypercholesterolemia and Atherosclerosis in Rabbits
Kim Tae-Myoung

Kim Yun-Bae
Ryu Jae-Myun
Seo Im-Kwon
Hwang Seok-Yeon
Lee Kyoung-Mi
Yeon Seong-Ho
Kang Shin-Jung
Abstract
The purpose of this study was to confirm the combinational effect of red ginseng powder (RGP) and silk peptide (SP) on hypercholesterolemia and atherosclerosis in rabbits. Male New Zealand White rabbits were fed only high-cholesterol diet (HCD) containing 0.5% cholesterol and 1% corn oil for 2 weeks, and then RGP (3%), SP (1% or 3%) or their combinations were added to a diet containing 0.25% cholesterol and 1% corn oil for additional 8 weeks. Blood total cholesterol and low-density lipoproteins (LDL) were greatly increased by 2-week feeding HCD to 13-15 folds of control, in contrast to the reduction of highdensity lipoproteins (HDL) to a half level. Additional 8-week feeding HCD caused thick atheromatous plaques, covering 65.8-67.3% of the aortic wall, and hepatocytic lipid peroxidation, leading to vacuolar and fatty degeneration. Such a hypercholesterolemia was significantly reduced by addition of RGP, in comparison with a mild effect of SP. In addition, HCD-induced decrease in HDL and increase in triglycerides were reversed by RGP and SP. Moreover, the atheroma area on the aortic wall as well as hepatocytic lipid peroxidation and degeneration were markedly attenuated by RGP. Especially, the effects of RGP on blood lipid profiles, atheroma formation and hepatocytic damage were potentiated by the combination of SP. The results suggest that RGP improves hypercholestarolemia and ensuing atherosclerosis, probably by both controlling lipid metabolism and reducing free radical reactions, which is synergistically enhanced by SP.
KEYWORD
Red ginseng powder, silk peptide, hypercholesterolemia, atherosclerosis
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed